|
Press Releases |
|
|
|
Thursday, May 2, 2019 |
|
雅各臣公布盈喜 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─ 雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布盈喜预告,就集团截至二零一九年三月三十一日止财政年度的未经审核综合管理财务报表之初步评估,预期集团之公司股东应占综合溢利较二零一八年三月三十一日止财政年度增加超过20%。 more info >> |
|
雅各臣公布盈喜 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈盈喜預告,就集團截至二零一九年三月三十一日止財政年度的未經審核綜合管理財務報表之初步評估,預期集團之公司股東應佔綜合溢利較二零一八年三月三十一日止財政年度增加超過20%。 more info >> |
|
Tuesday, December 13, 2016 |
|
雅各臣公佈完成收購「何濟公」之100%權益 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業—雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天宣佈完成收購目標集團(由「嘉倫藥業有限公司」、「永生藥業有限公司」及「香港何濟公藥廠有限公司」組成),該目標集團擁有傳統居家品牌「何濟公」之100%權益,總代價為568,000,000港元。 more info >> |
|
Thursday, May 2, 2019 |
|
Jacobson Pharma Issues Positive Profit Alert |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced a positive profit alert. more info >> |
|
Wednesday, November 21, 2018 |
|
雅各臣公布二零一九财年中期业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布公司及其附属公司(统称「集团」)于截至二零一八年九月三十日止六个月(「报告期」)的未经审核中期业绩。 more info >> |
|
雅各臣公佈二零一九財年中期業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈公司及其附屬公司(統稱「集團」)於截至二零一八年九月三十日止六個月(「報告期」)的未經審核中期業績。 more info >> |
|
Jacobson Pharma Announces FY2019 Interim Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2018 (the "reporting period"). more info >> |
|
Monday, June 25, 2018 |
|
Jacobson Pharma Announces 2018 Annual Results |
Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2018 ("FY2018"). more info >> |
|
雅各臣公布二零一八年全年业绩 |
从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司(「雅各臣」或「集团」;股份代号:2633)今天公布公司及其附属公司(统称「集团」)于截至二零一八年三月三十一日止年度(「二零一八财年」)的全年业绩。
more info >> |
|
雅各臣公佈二零一八年全年業績 |
從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司(「雅各臣」或「集團」;股份代號:2633)今天公佈公司及其附屬公司(統稱「集團」)於截至二零一八年三月三十一日止年度(「二零一八財年」)的全年業績。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
三菱商事、e-メタンの国際的アライアンス 「e-NG Coalition」 の設立について
Mar 19, 2024 12:30: JST
|
|
|
Hitachi Vantara Announces Collaboration with NVIDIA to Create New Portfolio of Industrial AI Solutions
Mar 19, 2024 12:35 JST
|
|
|
Discover BLUETTI AC240 All-Weather Power Solution: Power Beyond Limits, Rain or Shine
Mar 19, 2024 11:00 HKT/SGT
|
|
|
田中控股株式會社總公司搬遷 遷至創業地點茅場町的新總公司大樓
Mar 19, 2024 11:00 HKT/SGT
|
|
|
田中控股株式会社总公司搬迁 迁至创业之地茅场町的新总公司大楼
Mar 19, 2024 11:00 HKT/SGT
|
|
|
SAP與NVIDIA攜手加速推動全球企業應用生成式AI
Mar 19, 2024 10:54 HKT/SGT
|
|
|
SAP and NVIDIA to Accelerate Generative AI Adoption Across Enterprise Applications Powering Global Industries
Mar 19, 2024 10:53 HKT/SGT
|
|
|
富士通、採用計画について
Mar 19, 2024 10:30: JST
|
|
|
TANAKA 홀딩스, 본사를 창업지 카야바초 새로운 본사 빌딩으로 이전
Mar 19, 2024 10:00 HKT/SGT
|
|
|
Fujitsu Limited announces recruitment plans
Mar 19, 2024 10:34 JST
|
|
|
Raychem RPG achieves significant milestone to facilitate faster execution in electricity distribution projects with its 'Make India' initiative
Mar 19, 2024 09:00 HKT/SGT
|
|
|
Seyond to Expand LiDAR Solutions for Autonomous Vehicles with NVIDIA DriveWorks and Omniverse Integration
Mar 19, 2024 08:00: JST
|
|
|
Seyond to Expand LiDAR Solutions for Autonomous Vehicles with NVIDIA DriveWorks and Omniverse Integration
Mar 19, 2024 07:00 HKT/SGT
|
|
|
亿胜生物公布2023年度业绩,收入增长29.5%,利润增长22.1%
Mar 18, 2024 21:32 HKT/SGT
|
|
|
億勝生物公布2023年度業績,收入增長29.5%,利潤增長22.1%
Mar 18, 2024 21:31 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|